Iterative Health closed a $77 million Series C round to expand trial operations and accelerate enrollment. The company said it will deepen capabilities in cardiology and obesity trials, invest further in AI to support trial success, and scale provider and sponsor partnerships. Backers included Intrepid Growth Partners and Google Ventures, alongside EDBI and existing investors Insight Partners and Obvious Ventures. Iterative also highlighted operational claims such as faster research site activation and improved patient enrollment rates versus industry averages. The funding is a reminder that trial-enrollment infrastructure—especially AI-enabled site activation—continues to attract capital as sponsors seek speed and predictability in clinical development.